News - Boehringer Ingelheim


Current filters:

Boehringer Ingelheim

Popular Filters

151 to 175 of 184 results

Flood of new cancer drug data presented at ASCO; nearly 1,000 being tested


The annual prestigious American Society of Clinical Oncology (ASCO) meeting taking place in Chicago,…

afatinibBiotechnologyBoehringer IngelheimGenentechJanssenJohnson & JohnsonOncologyPharmaceuticalResearchRochetrastuzumab emtansineZytiga

EMA unit backs approval of Jentadueto; Agency updates on Pradaxa


Independent German drug major Boehringer Ingelheim and US partner Eli Lilly (NYSE: LLY) have received…

Boehringer IngelheimCardio-vascularDiabetesEli LillyEuropeJentaduetoPharmaceuticalPradaxaRegulation

UK academia-pharma collaboration attracts £14.4 million funding


In the UK, the University of Dundee and the Medical Research Council (MRC) have announced new funding…

AstraZenecaBoehringer IngelheimEuropeFinancialGlaxoSmithKlineJohnson & JohnsonMerck SeronoPfizerPharmaceuticalResearch

Breckenridge in generic Viramune deal with Zhejiang Huahai Pharma


Privately-held US generic drugmaker Breckenridge Pharmaceutical that it has finalized its agreement with…

Anti-viralsAsia-PacificBoehringer IngelheimBreckenridge PharmaceuticalsGenericsMarkets & MarketingNevirapineNorth AmericaPatentsViramuneZhejiang Huahai Pharma

Boehringer Ingelheim says it is on growth path, as 2011 sales rise 6.2%


German family-owned drug major Boehringer Ingelheim yesterday announced its financial results for full-year…

Boehringer IngelheimFinancialPharmaceutical

Promethera raises 23.6 million euros, with backers including Shire and Boehringer


Belgian cell therapy company Promethera Biosciences yesterday completed a fundraising round that generated…

BiotechnologyBoehringer IngelheimFinancialHepaStemNephrology and HepatologyPromethera BiosciencesRegulationShire

Ablynx extends Nanobody deal with Boehringer


Belgian drug developer Ablynx (Euronext Brussels: ABLX) yesterday announced a two-year extension of the…

AblynxBiotechnologyBoehringer IngelheimImmunologicalsLicensingOncologyPharmaceuticalRespiratory and Pulmonary

Caelyx and Ceplene manufacturing should be moved, says EMA


The European Medicines Agency has recommended that the manufacturing processes for the anticancer medicines…

Boehringer IngelheimCaelyxCepleneEpiCeptJanssen-CilagJohnson & JohnsonOncologyPharmaceuticalRegulationRespiratory and Pulmonary

NICE recommends NHS use of Pradaxa


In final guidance published today (March 15), the UK drug watchdog the National Institute of Health and…

Boehringer IngelheimCardio-vascularEuropePharmaceuticalPradaxaPricingRegulation

Boehringer Ingelheim links with Xencor on MAb supply


Independent German drug major Boehringer Ingelheim has entered into a collaboration agreement with USA-based,…

BiotechnologyBoehringer IngelheimLicensingPharmaceuticalXencor

FDA approves combo diabetes drug Jentadueto and Kalydeco


The US Food and Drug Administration) has approved Jentadueto (linagliptin/metformin hydrochloride) tablets,…

Boehringer IngelheimDiabetesEli LillyJentaduetoKalydecolinagliptinNorth AmericaPharmaceuticalRare diseasesRegulationVertex

Added benefit of Trajenta not proven, says German agency


In an early benefit assessment under Germany’s "Act on the Reform of the Market for Medicinal Products”…

Boehringer IngelheimDiabetesEli LillyEuropePharmaceuticalRegulationTrajenta

FORMA Thera in up to $815 million deal with Boehringer


Fast-growing US drug discovery firm FORMA Therapeutics has entered into an R&D collaboration with family-owned…

Boehringer IngelheimFORMA TherapeuticsOncologyPharmaceuticalResearch

UK ABPI gears up for next pricing negotiations; Boehringer breaches code


The Associations of the British Pharmaceutical Association (ABPI) last Friday brought together pharmaceutical…

Boehringer IngelheimEuropeMarkets & MarketingPharmaceuticalPradaxaPricing

COPD market to grow to more than $13.4 billion in 2020


As a result of an expanding aging population, increases in drug treatment and the uptake of premium priced…

Boehringer IngelheimGlobalMarkets & MarketingolodaterolPharmaceuticalRespiratory and Pulmonarytiotropium

Boehringer expands in China; Lundbeckfond ups ALK-Abello stake


Family-owned German drug major Boehringer Ingelheim says it intends to invest 70 million euros ($91 million)…

Alk-AbelloAsia-PacificBoehringer IngelheimEuropeFinancialLundbeckfondPharmaceutical

FDA reviews Pradaxa bleeding risk


Post-marketing reports of serious bleeding events in patients taking Pradaxa (dabigatran etexilate mesylate),…

Boehringer IngelheimCardio-vascularNorth AmericaPharmaceuticalPradaxaRegulation

EMA makes interim recommendations to deal with shortcomings at Ben Venue Labs


The European Medicines Agency (EMA) is currently reviewing shortcomings in quality assurance identified…

Boehringer IngelheimEuropeMarkets & MarketingNorth AmericaPharmaceuticalRegulation

EMA says bleeding risks associated with Boehringer Ingelheim’s Pradaxa can be managed


The European Medicines Agency on Friday providing an update on the safety of independent German drug…

Boehringer IngelheimCardio-vascularEuropePharmaceuticalPradaxaRegulation

Boehringer Ingelheim invests over $350 million in 2011 US expansion projects


Privately-held German drug major Boehringer Ingelheim says that it has made more than $350 million worth…

Boehringer IngelheimFinancialNorth AmericaPharmaceuticalResearch

UK NICE recommends Boehringer’s Pradaxa for stroke prevention


In final draft guidance published today (November 1), the UK’s drug watchdog the National Institute…

Boehringer IngelheimCardio-vascularEuropePharmaceuticalPradaxaPricingRegulation

Benefits of Boehringer’s Pradaxa come at high cost, study finds


Treating patients with the new blood thinning medication dabigatran (German independent drug major Boehringer…

Boehringer IngelheimCardio-vascularNorth AmericaPharmaceuticalPradaxaPricing

Boehringer Ingelheim’s Combivent Respimat Inhalation Spray OKed in USA to replace aerosol


The US Food and Drug Administration has approved German independent drug major Boehringer Ingelheim’s…

Boehringer IngelheimCombiventNorth AmericaPharmaceuticalRegulationRespiratory and Pulmonary

Boehringer license novel HIV non-catalytic integrase inhibitors to Gilead


Two of the big names in HIV/AIDS drug research and marketing, the USA’s Gilead Sciences (Nasdaq:…

Anti-viralsBoehringer IngelheimGilead SciencesLicensingPharmaceutical

151 to 175 of 184 results

Back to top